A study comparing active methamphetamine use, remission and healthy controls found a more complicated pattern than uniform cognitive impairment. Its results do not show that continuing methamphetamine use protects cognition or that stopping causes cognitive decline.
Huckans and colleagues administered the Neuropsychological Assessment Battery to adults with active use, adults in remission from methamphetamine use disorder and controls without a substance-use-disorder history. The abstract reports group sizes of 36, 48 and 62, respectively.
Different people occupied the three groups. The study did not randomize people to use or abstain and did not follow a single group through a controlled withdrawal process. That design distinction is crucial when interpreting differences between active use and remission.
The active-use group did not perform significantly worse than controls on any battery index. The remission group scored significantly lower than controls on the Memory Index. The active-use group also scored significantly higher on the Executive Functions Index than both other groups.
These are the comparisons reported by the study. They should not be simplified into either “all methamphetamine users are cognitively impaired” or “methamphetamine improves cognition.” A nonsignificant disadvantage does not demonstrate equivalence, and an observational advantage does not establish a drug-induced benefit.
The groups differed in age, education, sex distribution, psychiatric diagnoses and tobacco use. For example, the remission group had fewer years of education, and controls had fewer psychiatric diagnoses and lower tobacco-use rates. Statistical adjustments can address measured differences, but they cannot reproduce random assignment or exclude all unmeasured influences.
The study therefore raises useful questions about cognitive challenges during recovery while leaving their causal explanation uncertain. Individual variation remains important, and group means cannot establish a person’s ability at a particular time.
Clinicians and experts can use the paper to question oversimplified assumptions about recovery and to identify cognitive domains requiring assessment. Causal claims require stronger designs. See our separate discussion of longitudinal cognitive change during abstinence.
Read the primary study (DOI: 10.1080/13803395.2021.1976734).